Insider Selling: St. Jude Medical VP Sells 5,024 Shares of Stock (STJ)
St. Jude Medical (NYSE:STJ) VP Mark Murphy unloaded 5,024 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $57.51, for a total transaction of $288,930.24. Following the completion of the transaction, the vice president now directly owns 1,146 shares of the company’s stock, valued at approximately $65,906. The transaction was disclosed in a filing with the SEC, which is available at this link.
St. Jude Medical (NYSE:STJ) traded down 0.91% during mid-day trading on Wednesday, hitting $57.82. 1,875,983 shares of the company’s stock traded hands. St. Jude Medical has a one year low of $30.25 and a one year high of $54.06. The stock has a 50-day moving average of $52.21 and a 200-day moving average of $46.01. The company has a market cap of $16.883 billion and a P/E ratio of 23.83.
St. Jude Medical (NYSE:STJ) last posted its quarterly earnings results on Wednesday, October 16th. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.89 by $0.01. The company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the company posted $0.83 earnings per share. St. Jude Medical’s revenue was up .9% compared to the same quarter last year. On average, analysts predict that St. Jude Medical will post $3.73 earnings per share for the current fiscal year.
STJ has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of St. Jude Medical from $40.00 to $44.00 in a research note to investors on Thursday, October 17th. They now have an “underperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of St. Jude Medical in a research note to investors on Thursday, October 17th. They now have a $59.00 price target on the stock. Finally, analysts at Credit Suisse raised their price target on shares of St. Jude Medical from $55.00 to $60.00 in a research note to investors on Thursday, October 17th. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $49.80.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.